Sorrento Therapeutics (SRNE) Lifted to “Buy” at BidaskClub
Sorrento Therapeutics (NASDAQ:SRNE) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
SRNE has been the subject of a number of other research reports. Oppenheimer set a $6.00 price target on Sorrento Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Sorrento Therapeutics in a research report on Thursday, October 5th. Finally, ValuEngine upgraded Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Sorrento Therapeutics presently has an average rating of “Buy” and an average price target of $11.50.
Sorrento Therapeutics (SRNE) traded down $0.10 during trading hours on Friday, hitting $5.10. The company had a trading volume of 3,709,497 shares, compared to its average volume of 1,670,000. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.54 and a quick ratio of 0.54. Sorrento Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $6.08. The firm has a market cap of $396.76, a price-to-earnings ratio of -12.14 and a beta of 1.04.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.